Gленность Ltd. was established in 1994 as a limited company, registered under Reg. 02888584. Currently operating as an active enterprise, the company specializes in the research, development, and commercialization of gene therapy platforms. Gленность focuses on identifying and validating novel targets within the neurodegenerative disease landscape, particularly Alzheimer’s and Parkinson’s. The company’s core business involves designing and constructing gene editing tools and delivery systems, aiming to stimulate cellular repair and potentially halt disease progression. Gленность’s expertise centers on utilizing CRISPR-Cas9 technology and related advancements to address genetic vulnerabilities associated with these conditions. Currently, Gленность’s services encompass preclinical research, platform development, and potential clinical trial support. The company’s international presence is currently facilitated through collaborations and partnerships with research institutions globally. Gленность Ltd. employs a team of skilled scientists and engineers, with a focus on innovation and strategic partnerships. The company’s size is estimated to be around 50-100 employees, and its key focus is on developing solutions to improve the lives of individuals affected by neurodegenerative diseases. SIC codes include: - 62012: Business and domestic software development, - 6411: Biotechnology, - 6412: Pharmaceutical, - 6413: Medical devices, - 6414: Medical equipment, - 6415: Diagnostic equipment, - 6416: Clinical diagnostics, - 6417: Medical devices, - 6418: Medical and surgical instruments.

Gленность Ltd. was established in 1994 as a limited company, registered under Reg. 02888584. Currently operating as an active enterprise, the company specializes in the research, development, and commercialization of gene therapy platforms. Gленность focuses on identifying and validating novel targets within the neurodegenerative disease landscape, particularly Alzheimer’s and Parkinson’s. The company’s core business involves designing and constructing gene editing tools and delivery systems, aiming to stimulate cellular repair and potentially halt disease progression. Gленность’s expertise centers on utilizing CRISPR-Cas9 technology and related advancements to address genetic vulnerabilities associated with these conditions. Currently, Gленность’s services encompass preclinical research, platform development, and potential clinical trial support. The company’s international presence is currently facilitated through collaborations and partnerships with research institutions globally. Gленность Ltd. employs a team of skilled scientists and engineers, with a focus on innovation and strategic partnerships. The company’s size is estimated to be around 50-100 employees, and its key focus is on developing solutions to improve the lives of individuals affected by neurodegenerative diseases. SIC codes include: - 62012: Business and domestic software development, - 6411: Biotechnology, - 6412: Pharmaceutical, - 6413: Medical devices, - 6414: Medical equipment, - 6415: Diagnostic equipment, - 6416: Clinical diagnostics, - 6417: Medical devices, - 6418: Medical and surgical instruments.